NeuroSearch and BI deal

Published: 18-Apr-2002


Shares in Denmark's NeuroSearch jumped more than 30% after the firm unveiled a US$80m (€91m) deal with private German company Boehringer Ingelheim (BI). The alliance covers the former's NS2330, a compound designed to treat dementia associated with Alzheimer's (AD) and Parkinson's diseases, and gives BI marketing rights in all countries around the world with a few exceptions.

BI will assume costs related to the ongoing development of the compound, which has a novel mechanism of action in that it boosts levels of three chemicals found in the brain – acetyl-choline, noradren-aline and dopamine. NS2330 has recently completed a Phase IIa clinical trial on AD, in which the treated patients saw a good improvement in their memory function.

You may also like